Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing.

Clinical pharmacology and therapeutics - 1 Jan 2021

Zhou Yitian, Krebs Kristi, Milani Lili, Lauschke Volker M

Abstract excerpt

Immune-mediated drug hypersensitivity reactions are an important source of iatrogenic morbidity and mortality. Human leukocyte antigen (HLA)-B*57:01, HLA-B*15:02, HLA-A*31:01, and HLA-B*58:01 constitute established risk factors and preemptive genotyping of these HLA alleles in patients prior to the initiation of abacavir, carbamazepine, and allopurinol-based therapies can prevent toxicity and improve patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allopurinol
Share to Asia
Share to Carbamazepine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Dideoxynucleosides

Share to Drug Hypersensitivity

Share to HLA Antigens

Share to Pharmacogenomic Testing

Source

Identifiers

PMID: 32535895
DOI: 10.1002/cpt.1944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing.PMID 32535895Read ↗

Cost‐Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation FrameworkSemantic proximity Read ↗

Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.Semantic proximity Read ↗

Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.Semantic proximity Read ↗

Developing pharmacogenetic screening methods for an emergent country: VietnamSemantic proximity Read ↗

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.Semantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions.Semantic proximity Read ↗

HLA pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the Greater Middle East.Semantic proximity Read ↗

Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model.Semantic proximity Read ↗

HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience.Semantic proximity Read ↗

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.